Anti- Amylod BA4;clone1E8(AminoTerminus)

Application

Research Sub CategoryNeurodegenerative Diseases

This Anti-Amyloid βA4, clone 1E8 (Amino Terminus) Antibody is validated for use in western blotting, IHC & IP for the detection of Amyloid βA4.

Research CategoryNeuroscience

Immunohistochemistry Analysis: A 1:500-2,000 dilution from a representative lot was used to detect Amyloid βA4 in human Alzheimer′s brain and thalamus tissues.

Western Blotting Analysis: A representative lot was used to detect Amyloid βA4 in Western Blotting. (Wiltfang, et al. 2001; Serneels, et al. 2009; Maler, et al. 2007).

Immunoprecipitation Analysis: A representative lot was used to detect Amyloid βA4 in Immunoprecipitation. (Wiltfang, et al. 2001; Maler, et al. 2007).

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

Amyloid beta A4 protein, also known as ABPP or APPI (APP) or Alzheimer disease amyloid protein or Cerebral vascular amyloid peptide (CVAP) or PreA4 or Protease nexin-II (PN-II), and encoded by the gene name APP or A4 or AD1, belongs to the APP family. The beta-amyloid peptide (beta A4), proteolytically released from the amyloid precursor protein (APP), is the principal component of senile plaques in Alzheimer′s disease. Cleavage of APP by alpha-secretase or alternatively by beta-secretase leads to generation and extracellular release of soluble APP peptides, S-APP-alpha and S-APP-beta, respectively, and the retention of corresponding membrane-anchored C-terminal fragments, C83 and C99. Subsequent processing of C83 by gamma-secretase yields P3 peptides. This is the major secretory pathway and is nonamyloidogenic. Alternatively, presenilin/nicastrin-mediated gamma-secretase processing of C99 releases the amyloid beta proteins, amyloid-beta 40 (Abeta40) and amyloid-beta 42 (Abeta42), major components of amyloid plaques, and the cytotoxic C-terminal fragments, gamma-CTF(50), gamma-CTF(57) and gamma-CTF(59). Mab βA4N-1E8 recognizes the free N-terminus of the bA4 polypeptide with high preference and crossreacts with sAPPA.

Immunogen

KLH-conjugated peptide corresponding to the N-terminus of human Amyloid βA4.

Epitope: N-terminus

Physical form

Affinity

Purified mouse monoclonal IgG1κ in buffer containing PBS, PEG, Sucrose, and up to 0.1% sodium azide.

Quality

Evaluated by Western Blotting in human Alzheimer′s brain tissue lysate.

Western Blotting Analysis: A 1:1,000 dilution of this antibody detected Amyloid βA4 in human Alzheimer′s brain tissue lysate.

Specificity

This antibody is specific for the first 2 amino acids of the Amyloid beta peptide amino terminus.

Storage and Stability

For long-term storage, freeze lyophilizate upon arrival (2-8°C). Upon reconstitution, aliquote and freeze in liquid nitrogen; reconstituted antibody can be stored frozen at -80°C up to 1 year. Thaw aliquots at 37°C. Thawed aliquots may be stored at 4°C up to 3 months.

Avoid repeated freeze / thaw cycles.

Target description

~4 kDa observed. Uncharacterized bands may be observed in some lysate(s).